Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
ACS Med Chem Lett
; 12(3): 380-388, 2021 Mar 11.
Article
in En
| MEDLINE
| ID: mdl-33738065
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
ACS Med Chem Lett
Year:
2021
Document type:
Article
Affiliation country:
Reino Unido